REVIEW ARTICLE

Biological Sciences
(An International Journal of Medical, Pharmaceutical, and Life Sciences)

Journal home: https://irrespub.com/biolsciences/index.php/1/index



Advancements in Microbial Drug Discovery: Leveraging AI, CRISPR, and Microbiome Insights to Overcome Antimicrobial Resistance

Ibrahim Abdulrazaq[1]*, Shehu-Alimi Elelu[2], Ganiyat Omotayo Ibrahim[3], Idowu Afeez Temitope[4], Abdulsalam Hawau Avoswahi[5], Abdulkareem Tajuddeen Zakari[6], Mustapha Abdulsalam[7]

[1&6]Department of Microbiology, University of Ilorin, Nigeria; [2]Department of Chemistry, Howard University, Washington DC, USA; [3]Department of Chemistry, Nottingham Trent University, UK; [4]Department of Medicinal Research, Kaohsiung Medical University Hospital, Taiwan, [5]Department of Computer Sciences, University of Ilorin, Nigeria, [7]Department of Microbiology, Skyline University, Nigeria.

ARTICLE HISTORY

Received: 13-12-2024
Revised: 16-05-2025
Accepted: 01-08-2025
Online: 02-09-2025

KEYWORDS

Artificial intelligence
CRISPR technology
Antimicrobial resistance
Microbiome
Drug discovery

ABSTRACT

This study explores the innovative intersection of artificial intelligence (AI), CRISPR technology, and microbiome insights in microbial drug discovery, with a focus on overcoming the challenges posed by antimicrobial resistance (AMR) and emerging infectious diseases. The global threat of AMR necessitates the development of novel approaches that transcend traditional drug discovery methods. AI-driven platforms, including machine learning and high-throughput screening, are transforming drug design by enabling rapid identification of potential therapeutic targets and optimizing drug repurposing efforts. CRISPR-based gene-editing technologies offer precise tools to combat resistance mechanisms at the genetic level, while microbiome-based therapies hold promise for restoring microbial balance and improving immune responses. Despite significant progress, several challenges remain, including the integration of these technologies, data quality concerns, and the clinical translation of innovative solutions. The future of microbial drug discovery lies in the synergy of these technologies, providing a pathway toward personalized, effective treatments and combating the growing threat of AMR. This study provides a comprehensive overview of the current landscape, identifies research gaps, and outlines potential directions for future advancements.

*Address for correspondence
Department of Microbiology, University of Ilorin, Nigeria.
Email: ibroabdulrazaq@gmail.com
DOI: https://doi.org/10.55006/biolsciences.2025.5304
Published by IR Research Publication;

Introduction

Antimicrobial resistance (AMR) has emerged as one of the most pressing global health challenges. The World Health Organization (WHO) has identified AMR as a major threat to public health, estimating that by 2050, drug-resistant infections could lead to more deaths than cancer (1). AMR occurs when microorganisms, including bacteria, fungi, viruses, and parasites, evolve to resist the drugs that once killed them or inhibited their growth. This resistance

is often a result of overuse and misuse of antibiotics in both human and veterinary medicine, combined with poor infection control practices. The rapid spread of resistant strains poses a serious risk to the treatment of common infections, making routine surgeries and treatments increasingly dangerous (2). The rise of multidrug-resistant organisms, such as Carbapenem-resistant Enterobacteriaceae and Methicillin-resistant Staphylococcus aureus (MRSA), significantly limits therapeutic options, increasing mortality rates and healthcare costs (3).

Traditional methods of drug discovery face significant challenges in combating AMR. Historically, the development of antibiotics involved the identification of microbial targets, followed by screening for compounds that could inhibit these targets. However, this process has slowed considerably in recent decades. One major challenge is the high cost and lengthy timeframes associated with bringing a new drug to market, spanning 10–15 years (4). Moreover, the complexity of drug-resistant pathogens, which often harbor multiple resistance mechanisms, makes it difficult to identify effective compounds that can overcome these challenges. Furthermore, the increasing difficulty in identifying new targets for antibiotic action has led to a stagnation in the development of novel drug classes. With a focus on short-term profits, the pharmaceutical industry has also shifted its attention to more lucrative areas such as chronic disease treatments, often leaving the antimicrobial sector underfunded (5).

Emerging technologies offer promising solutions to address the challenges in antimicrobial drug discovery. Advances in artificial intelligence (AI) and machine learning (ML) have revolutionized drug discovery, enabling faster identification of potential antimicrobial candidates by predicting the effectiveness of compounds against resistant pathogens (6). AI algorithms can process large datasets, identifying patterns that would be impossible for humans to detect, accelerating drug development. In addition, technologies like CRISPR-based gene editing allow for precise manipulation of microbial genomes, which can help researchers identify novel drug targets and understand resistance mechanisms at a molecular level (7). Furthermore, innovations in microbiome research are providing new insights into the role of human microbiota in shaping pathogen resistance. Targeting the microbiome could lead to more sustainable treatments that reduce the overuse of antibiotics and minimize resistance development (8). By integrating these technologies, researchers can optimize the drug discovery process, identify new antimicrobial agents more efficiently, and potentially overcome the resistance crisis.

Artificial Intelligence in Microbial Drug Discovery

Machine learning applications in antimicrobial drug design

Machine learning (ML) has rapidly emerged as a powerful tool in the design of antimicrobial agents, transforming how researchers identify and develop new drugs. In traditional drug discovery, researchers manually test thousands of compounds to find effective agents against specific pathogens. This process is both time-consuming and expensive. ML algorithms, however, can analyze vast amounts of biological and chemical data to predict potential drug candidates much more efficiently. By leveraging large datasets that contain information about the molecular structure of compounds, ML models can predict how different chemical compounds will interact with microbial targets, identify novel antimicrobial properties, and even anticipate the likelihood of resistance development (9). Moreover, ML techniques such as supervised learning, unsupervised learning, and deep learning have been employed to analyze molecular interactions, protein-ligand binding, and toxicity profiles of drug candidates, which significantly accelerates the drug design process. Researchers have applied these approaches to generate virtual libraries of compounds, which can be used to design drugs that are specifically tailored to combat resistant pathogens (10). By enabling high throughput in silico screening, machine learning is reducing the need for traditional experimental testing, making the drug discovery process both faster and more cost-effective.

AI for drug repurposing and target identification

Artificial intelligence has also shown significant promise in drug repurposing, which involves finding new uses for existing drugs. Given the urgent need to combat resistant pathogens, repurposing FDA-approved drugs can provide a more rapid path to new treatments compared to developing drugs from scratch. AI models can predict how existing compounds might interact with new targets, including those in drug-resistant bacteria, thereby identifying new indications for drugs that were not originally intended for antimicrobial use (11). Furthermore, AI-driven approaches have been critical in target identification, an essential step in the drug discovery process. Traditional methods for target identification are labor-intensive and often based on serendipitous discoveries. AI, however, can analyze complex datasets such as genomic, transcriptomic, and proteomic data to identify novel targets within microbial pathogens. For example, deep learning algorithms have been successfully employed to predict protein-protein interactions and uncover potential therapeutic targets in multi-

drug resistant organisms (12). By combining AI with high-throughput biological data, researchers can pinpoint vulnerabilities in microbial pathogens that can be exploited for drug development.

AI-driven high-throughput screening and optimization

High-throughput screening (HTS) is a critical component of modern drug discovery, allowing researchers to test large libraries of compounds for activity against specific pathogens. Traditional HTS methods involve screening thousands of compounds in experimental assays, which is both time- and labor-intensive. AI has revolutionized HTS by automating the screening process and optimizing it through machine learning algorithms that analyze results faster and more accurately than traditional methods. For instance, AI can rapidly predict the efficacy of compounds based on their chemical properties, structure-activity relationships, and the genetic makeup of pathogens, thus narrowing down the most promising candidates for further testing (13). Furthermore, AI can be used to optimize the drug discovery process by predicting the pharmacokinetics and pharmacodynamics of candidate drugs. This predictive capability allows for the identification of compounds that are not only effective against pathogens but also safe for human use. Through iterative cycles of AI-driven optimization, researchers can improve the drug-like properties of compounds, such as bioavailability, stability, and toxicity profiles, ensuring that the identified compounds have the best chance of success in clinical trials (14). AI technologies are also being used to identify synergistic drug combinations, which could prove particularly useful in overcoming multi-drug resistance in pathogens.

CRISPR Technology in Microbial Drug Discovery

CRISPR as a tool for the genetic manipulation of microbes

The CRISPR-Cas system, originally discovered as a bacterial defense mechanism against viral infections, has since revolutionized genetic engineering, including in microbial drug discovery. The system allows precise and targeted manipulation of the genomes of various microorganisms, offering a powerful tool for investigating microbial function and developing novel antimicrobial strategies. CRISPR technology enables the knockout or activation of specific genes within microbial genomes, facilitating the study of their roles in pathogenicity, drug resistance, and susceptibility to antimicrobial agents (15). By using CRISPR to edit bacterial genes, researchers can identify essential genes that are crucial for survival, growth, or virulence, which could be exploited as novel drug targets. For example, CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) allow for reversible modulation of gene expression in bacteria without causing permanent mutations, making it easier to study gene function dynamically. These tools have been successfully employed in bacteria like Escherichia coli and Staphylococcus aureus to dissect the genetic basis of antibiotic resistance and pathogenicity (16). Through targeted genetic manipulation, CRISPR can help uncover new insights into microbial biology and provide valuable data for drug discovery.

Targeting resistance mechanisms using CRISPR-CAS systems

The rise of antimicrobial resistance (AMR) is one of the most significant challenges facing modern medicine. CRISPR-Cas technology has shown great promise in addressing AMR by enabling the targeted disruption of resistance mechanisms within microbial pathogens. By utilizing CRISPR to edit genes that confer resistance to antibiotics, researchers can reverse resistance in drug-resistant strains and restore the effectiveness of existing antimicrobial agents (17). For instance, CRISPR has been used to knock out genes that encode for enzymes like beta-lactamases in Escherichia coli and Pseudomonas aeruginosa, which confer resistance to beta-lactam antibiotics (18). This ability to counteract resistance mechanisms directly within pathogens offers a promising avenue for the development of novel therapeutic strategies. Moreso, CRISPR-based technologies are being developed to target resistance genes in biofilms, a major challenge in chronic infections and medical device-related infections (19). By effectively disabling resistance pathways, CRISPR can not only help revive the use of existing antibiotics but also enable the development of new strategies to combat multidrug-resistant infections.

The potential of CRISPR for new antimicrobial target discovery

In addition to its role in genetic manipulation and resistance reversal, CRISPR technology holds immense potential in discovering new antimicrobial drug targets. One of the most promising applications of CRISPR in drug discovery is its use in high-throughput screening to identify essential genes in pathogens that could be targeted by new drugs. CRISPR-based screens, such as CRISPR knockout libraries, allow researchers to systematically knock out genes in large pools of bacterial cells and assess their impact on survival or antibiotic susceptibility. This approach helps identify novel drug targets that are essential for pathogen viability but absent in the human host, thus reducing

the risk of off-target effects (20). Moreover, CRISPR can be used to explore the genetic basis of pathogenicity, metabolic pathways, and virulence in bacteria, enabling the identification of new classes of antibiotics that target previously unexplored microbial pathways. For example, recent studies have applied CRISPR to screen for potential drug targets in Mycobacterium tuberculosis, the causative agent of tuberculosis, revealing several novel genes essential for bacterial survival that could serve as potential therapeutic targets (21). Moreso, CRISPR is being integrated with other high-throughput techniques, such as RNA sequencing and proteomics, to identify microbial factors associated with antimicrobial resistance and virulence, facilitating the discovery of next-generation antimicrobial agents.

Microbiome Insights and Therapeutic Applications

Role of the human microbiome in infectious disease

The human microbiome, consisting of trillions of microorganisms residing primarily in the gut, skin, respiratory tract, and other mucosal surfaces, plays a crucial role in maintaining health and preventing infection. Recent research has revealed that disruptions in the microbiome, known as dysbiosis, can contribute to a wide range of infectious diseases, chronic conditions, and immune dysfunctions. The microbiome is integral to the immune system's function, with microbial communities interacting with immune cells to modulate immune responses and defend against pathogens (22). Dysbiosis has been associated with the development of various infectious diseases, including gastrointestinal infections caused by Clostridium difficile, respiratory infections like pneumonia, and even systemic infections resulting from immunocompromised states (23). Furthermore, the microbiome has been shown to influence the body's susceptibility to viral infections such as influenza and COVID-19, by modulating the inflammatory responses and immune system activity (24). As such, understanding the relationship between the human microbiome and infectious diseases has opened new avenues for preventive and therapeutic strategies in microbiology and immunology (**Figure 1**).

Microbiome-based drug discovery: a novel approach

Microbiome-based drug discovery represents a novel frontier in therapeutic development, with growing evidence supporting the impact of microbial communities on drug metabolism, disease progression, and treatment efficacy. Traditional drug discovery often overlooks the role of the microbiome in disease mechanisms and drug responses. However, recent studies suggest that the microbiome can influence the pharmacokinetics and pharmacodynamics of drugs, including their absorption, distribution, metabolism, and elimination (25). This has led to the exploration of microbiome-targeted therapies that either manipulate the microbiome directly or develop drugs that interact with microbial populations to enhance therapeutic outcomes. For example, the microbiome is now recognized as a crucial factor in the metabolism of cancer therapies, antibiotics, and immunosuppressants. Certain bacterial strains can enhance the efficacy of chemotherapy by modulating the immune response, while others can inactivate therapeutic agents, reducing their effectiveness (26). Drug discovery efforts are now integrating microbiome data to identify microbial-based biomarkers that predict drug responses, enabling more personalized treatments. Furthermore, probiotics, prebiotics, and fecal microbiota transplants (FMT) are being investigated as adjunct therapies to restore a healthy microbiome and improve treatment outcomes, particularly in conditions like antibiotic-resistant infections, inflammatory bowel disease, and even cancer (27).

Restoring microbial balance for enhanced immune function

Restoring the balance of the human microbiome has become a therapeutic goal for enhancing immune function and preventing infectious diseases. A healthy microbiome supports immune regulation by promoting the development of regulatory T-cells, enhancing the production of antimicrobial peptides, and stimulating the production of specific cytokines that help combat infections (28). In contrast, dysbiosis, often caused by factors such as poor diet, antibiotic overuse, or chronic stress, can impair immune function and increase susceptibility to infections. Restoration strategies, such as fecal microbiota transplantation (FMT) and the use of probiotics or prebiotics, aim to re-establish a balanced microbial community. FMT, which involves transferring fecal material from a healthy donor to a recipient, has been successfully used to treat recurrent Clostridium difficile infections and is being explored for other conditions linked to microbiome imbalance, such as autoimmune diseases and inflammatory bowel disease (29). Probiotics, live beneficial bacteria, and prebiotics, compounds that promote the growth of beneficial bacteria, are also being investigated for their potential to enhance immune responses and reduce the risk of infections (30). Through these therapeutic approaches, the microbiome's influence on immune modulation can

be harnessed to prevent infections and improve overall health.

Artificial Intelligence (AI) and CRISPR technology hold great promise in revolutionizing drug discovery, but several challenges hinder their full



Figure 1. Microbiome insights and therapeutic applications: key connections and therapeutic pathways.

Research Gaps and Future Directions

Identifying gaps in current drug discovery models

Despite advancements in drug discovery models, significant gaps persist, especially in the context of antimicrobial resistance (AMR). Traditional drug discovery approaches, which focus on small molecule inhibitors targeting specific microbial proteins, have proven limited in their ability to address the growing crisis of AMR. Many of these models fail to account for the dynamic interactions between pathogens and host systems, resulting in high failure rates in clinical trials (31). Furthermore, there is a lack of comprehensive models that integrate data from diverse sources, such as genomic, proteomic, and metabolomics information, which could potentially provide deeper insights into microbial pathogenesis and resistance mechanisms. The reliance on isolated testing methods that neglect the role of the microbiome and its interplay with pathogens also poses a critical limitation. Moreover, traditional animal-based testing models, which often fail to replicate the human response to infection accurately, continue to dominate the field, highlighting the need for more innovative, human-relevant models. Future drug discovery models need to incorporate systems biology approaches, utilize advanced molecular simulations, and adopt in silico strategies to better simulate the complex interactions of host-pathogen dynamics (32).

Challenges in AI and CRISPR Integration for Drug Discovery

integration. AI-based approaches are increasingly being used for high-throughput screening, drug repurposing, and identifying potential therapeutic targets. However, the complexity of biological systems and the immense volume of data generated by these techniques present significant hurdles. One of the primary challenges in applying AI to drug discovery is ensuring that algorithms can accurately model the intricate interactions between drugs, pathogens, and human physiology (33). The integration of CRISPR technology, while revolutionary for its precision in gene editing, also faces limitations in its application to drug discovery. Off-target effects and the potential for unintended genetic mutations pose a risk, especially when editing microbial genomes to identify novel therapeutic targets. Moreover, CRISPR's applicability in high-throughput screening processes is still limited due to the technical expertise required, the need for specialized infrastructure, and regulatory hurdles in clinical applications (34). To overcome these challenges, interdisciplinary approaches that combine AI and CRISPR, along with enhanced data integration and validation processes, will be crucial in unlocking the full potential of these technologies in drug discovery.

Underexplored pathways in microbiome-based therapies

The human microbiome plays a crucial role in both the development of infectious diseases and the efficacy of treatments, yet microbiome-based therapies remain underexplored. Although recent studies have shown that microbiome modulation through probiotics, prebiotics, and fecal microbiota transplantation (FMT) can improve outcomes in

diseases like Clostridium difficile infections and inflammatory bowel disease, many areas of microbiome-based drug discovery are still in their infancy (35). One underexplored pathway in microbiome-based therapies is the role of microbiota in modulating the immune system's response to infections. Microbiome interactions with the immune system can influence pathogen clearance and inflammatory responses, yet the exact mechanisms remain poorly understood. Moreover, research into the role of the microbiome in drug resistance and its potential use in mitigating AMR is scarce. The identification of microbial communities that can outcompete pathogenic bacteria or disrupt biofilm formation could provide innovative approaches to combating resistant infections. Microbiome-based precision medicine, which tailors therapies based on an individual's microbial composition, is another promising avenue but requires further investigation to understand how to optimize these treatments effectively (36).

Addressing data quality and availability issues in AI models

AI-based drug discovery and microbiome research are heavily reliant on large-scale datasets. However, one of the most significant barriers to advancing these fields is the issue of data quality and availability. Many current datasets are either incomplete, biased, or lacking in diversity, leading to model inaccuracies. For example, genomic datasets often have a limited representation of diverse populations, which may result in AI models that are not generalizable across different demographics (37). In microbiome research, incomplete or inconsistent data from different platforms (e.g., metagenomic sequencing, proteomics) can affect the accuracy of predictions made by AI models regarding microbial community structure and function. Moreover, the lack of standardized methodologies for data collection and reporting makes it difficult to consolidate data across studies and platforms. To improve the accuracy and reliability of AI-driven drug discovery, there needs to be a concerted effort to develop high-quality, standardized, and publicly accessible datasets. Furthermore, enhancing data privacy and security measures will be essential, especially when dealing with sensitive health data (38).

Future research areas to enhance antimicrobial resistance solutions

Addressing antimicrobial resistance (AMR) is a major global health challenge that requires urgent research advancements. While there is growing interest in AI, CRISPR, and microbiome-based therapies, more research is needed to identify novel mechanisms of resistance, discover new drug targets, and design innovative therapeutic strategies. Future research should focus on understanding the genetic and biochemical pathways that confer resistance in bacteria, fungi, and viruses, particularly in the context of multi-drug resistance (MDR) and pan-drug resistance (PDR). Exploring alternative therapies, such as antimicrobial peptides, bacteriophages, and combination therapies, may offer solutions to the growing resistance crisis (39). Moreover, the integration of AI with other cutting-edge technologies, such as nanotechnology and organ-on-chip models, could offer innovative ways to combat infections without relying solely on traditional antibiotics. Fostering global collaborations to share knowledge, resources, and data will be crucial in accelerating the development of new solutions for AMR (40). **Figure 2** below simplified overview of critical research gaps and future directions in addressing drug discovery challenges and antimicrobial resistance (AMR). It highlights four key focus areas: Drug Discovery



Figure 2. Key research gaps and future directions in drug discovery and antimicrobial resistance.

Gaps, including limitations in clinical translation and host-pathogen models; Technological Barriers, such as the integration of AI and CRISPR technologies; Microbiome Challenges, emphasizing the underexplored role of the microbiome in modulating resistance and immunity; and Future AMR Strategies, calling for alternative therapies and global collaborations.

Integrating AI, CRISPR, and Microbiome Insights

Synergistic potential of combining these technologies

The integration of Artificial Intelligence (AI), CRISPR technology, and microbiome insights offers a synergistic approach to modern drug discovery, especially in the fight against antimicrobial resistance (AMR). AI excels in managing large datasets and identifying patterns that would be challenging for human researchers to detect, enabling it to rapidly analyze genomic, proteomic, and microbiome data (41). CRISPR technology, a powerful gene-editing tool, allows precise manipulation of microbial genomes, enabling researchers to uncover new drug targets and resistance mechanisms with high accuracy (42). Meanwhile, the human microbiome, a key player in both health and disease, is an untapped source of novel therapeutic insights, especially regarding microbial community dynamics and host-pathogen interactions (43). When combined, these technologies can work synergistically to accelerate drug discovery. AI can help identify critical genes and pathways involved in resistance, which CRISPR can then target and edit to better understand their role in disease progression. The microbiome provides an additional layer of complexity, as its composition affects both drug metabolism and the immune response to infections. AI-driven analysis of microbiome data can pinpoint specific microbial interactions that influence pathogenicity or resistance. By integrating CRISPR to modify the microbiome or target pathogenic microbes directly, researchers can uncover novel therapeutic strategies that involve microbial modulation, gene editing, and precision-targeted treatments. This holistic approach could lead to the development of more effective and personalized antimicrobial therapies (44).

Case studies of successful integrations in drug discovery

Recent case studies illustrate the potential of combining AI, CRISPR, and microbiome insights in drug discovery. For example, researchers have utilized AI to analyze vast amounts of microbiome data to identify novel biomarkers for disease diagnosis and treatment. A notable study demonstrated how AI models were trained on metagenomic data from patients with Clostridium difficile infection, identifying key microbiota alterations that contributed to disease progression. By combining these AI findings with CRISPR technology, researchers were able to manipulate the gut microbiome, restoring a balanced microbial community and improving patient outcomes (45). Another case study highlighted the integration of AI and CRISPR for the identification of novel antimicrobial targets. Researchers employed AI-based algorithms to analyze the genomic sequences of Escherichia coli and identified genes associated with multidrug resistance. Using CRISPR-Cas9, these genes were knocked out to observe changes in drug resistance patterns. This integration of AI and CRISPR allowed for more precise identification of resistance mechanisms and the development of new antimicrobial targets (Shin et al., 2020). Furthermore, a collaborative study combining microbiome insights with AI models aimed to optimize the use of bacteriophage therapy. By analyzing microbiome data from patients receiving bacteriophage therapy, AI algorithms were able to predict phage efficacy and optimize phage selection. This enabled more effective treatment strategies for infections caused by resistant bacteria, showcasing the power of microbiome-AI integration in advancing therapeutic interventions (47).

Overcoming challenges in multi-technology integration

While the potential benefits of integrating AI, CRISPR, and microbiome insights are clear, several challenges remain in successfully merging these technologies. One of the main challenges is data interoperability. The data generated by AI, CRISPR experiments, and microbiome studies are often stored in different formats, requiring significant effort to harmonize and analyze them in a unified framework. Standardization of data formats and the development of common databases are essential to facilitate the seamless integration of these technologies (48). Another significant challenge lies in the technical complexity of each individual technology. AI algorithms require large, high-quality datasets to function optimally, but obtaining such datasets, particularly those involving the human microbiome can be time-consuming and expensive. Furthermore, CRISPR gene editing, while precise, is still a relatively new technology and may involve off-target effects, especially in complex microbial genomes. Ensuring that CRISPR editing is both precise and safe when applied in the context of drug discovery remains a hurdle (49). Moreso, while microbiome-based therapies hold promise, understanding the full scope of the microbiome's role in health and disease is still in its early stages.

Many of the interactions between microbial species and their impact on human health are not yet fully understood. Integrating AI to model these complex microbiome-host dynamics could accelerate this process, but there are challenges in developing accurate models that account for the vast complexity of the microbiome (50). To overcome these challenges, interdisciplinary collaboration between microbiologists, AI specialists, bioinformaticians, and genetic engineers is essential. Developing standardized protocols for microbiome research, improving CRISPR precision, and advancing AI algorithms capable of processing complex, multimodal data will be key to successfully integrating these technologies into drug discovery pipelines (51).

Future Perspectives

Innovations on the horizon: next-generation approaches in drug discovery

The future of drug discovery, particularly in the context of antimicrobial resistance (AMR) and emerging pathogens, is poised for transformation with the development of next-generation approaches. Several promising innovations are on the horizon, including advancements in artificial intelligence (AI), machine learning (ML), and nanotechnology, which are set to revolutionize how drugs are discovered, developed, and delivered. AI and ML, for example, have already demonstrated their potential in accelerating drug discovery by analyzing vast datasets, identifying new therapeutic targets, and predicting drug efficacy and safety (52). These tools are becoming increasingly essential in the context of AMR, where traditional methods of drug discovery have been slow and inefficient due to the complexity of microbial resistance mechanisms.

Nanotechnology is also a promising frontier in drug discovery. Nanomaterials and nanosystems can be designed to deliver drugs more efficiently, target pathogens with precision, and reduce off-target effects. For instance, nanoparticle-based drug delivery systems can overcome the barriers posed by the bacterial cell wall, allowing for more effective antimicrobial therapies (53). Moreover, new approaches, such as the development of synthetic biology and gene-editing tools like CRISPR, hold the potential to address resistance by targeting specific genes involved in resistance mechanisms or by creating novel therapeutic agents that bypass traditional resistance pathways (54). These innovations are not only advancing the discovery of new antimicrobial agents but also enhancing the development of multifunctional therapies that can target pathogens more precisely, reducing the likelihood of resistance development.

Long-term impact on antimicrobial resistance and emerging pathogens

The long-term impact of these next-generation approaches on antimicrobial resistance and emerging pathogens could be profound. As AMR continues to rise, the traditional arsenal of antibiotics is becoming less effective, prompting urgent calls for novel strategies. The integration of AI, CRISPR, and nanotechnology in drug discovery and therapy is expected to lead to more effective and targeted treatments, helping to combat both resistant strains of bacteria and emerging pathogens that may otherwise evade current diagnostic and therapeutic strategies. AI and computational models have already shown great promise in predicting the emergence of new resistance patterns and in identifying molecular signatures of resistance (55). By using these models, researchers can anticipate shifts in pathogen behavior and respond more quickly with targeted therapeutic strategies. Furthermore, CRISPR-Cas systems, which allow for precise gene-editing in pathogens, hold the potential to eliminate resistance genes or even reprogram microbial communities to make them less pathogenic (56). Nanotechnology also provides a unique advantage in delivering treatments directly to the site of infection, ensuring that antimicrobial agents remain effective for longer periods and reduce the likelihood of resistance development (57). The development of these technologies could significantly reduce the burden of AMR over the next few decades, offering solutions to both chronic and emerging infectious diseases. Moreover, these advancements will likely result in the development of broad-spectrum antimicrobial agents capable of targeting a wide range of pathogens, which is critical in the era of global travel and the increasing threat of pandemics.

The road to personalized medicine in infectious disease treatment

Personalized medicine, which tailors treatment based on an individual's genetic profile and other factors, is becoming an increasingly important focus in the treatment of infectious diseases. In the context of antimicrobial resistance, personalized medicine could provide a much-needed solution by offering targeted therapies that consider a patient's unique microbiome, genetic predispositions, and the specific pathogen responsible for the infection. Personalized approaches could ensure that patients receive the most effective treatment, minimizing the use of broad-spectrum antibiotics and reducing the development of resistance. The combination of AI and genomic data is at the forefront of this movement. AI-driven algorithms can analyze a patient's genomic and microbiome data to predict which antibiotics or antimicrobial agents will be most

effective based on the pathogen's resistance profile (58). Moreover, precision medicine could enable the identification of biomarkers for early-stage infections, allowing for timely intervention and the prevention of more severe outcomes (59). As personalized medicine becomes more integrated into infectious disease treatment, it will likely result in more effective and less toxic therapies, improved patient outcomes, and a reduction in unnecessary antibiotic use, which in turn will help slow the progression of antimicrobial resistance. The development of diagnostic tools that can quickly identify the pathogen and its resistance profile will be essential for realizing the full potential of personalized treatment in infectious diseases (60).

Conclusion

This study has highlighted the critical need for innovative approaches in microbial drug discovery, particularly in the context of combating antimicrobial resistance (AMR) and addressing emerging infectious diseases. Traditional drug discovery methods have struggled to keep pace with the rapidly evolving landscape of microbial pathogens, which continue to develop resistance mechanisms that outpace the effectiveness of existing antibiotics. However, emerging technologies, including artificial intelligence (AI), CRISPR-Cas systems, and microbiome-based therapies, present promising avenues to bridge these gaps. AI, in particular, has shown immense potential in revolutionizing drug discovery by enabling faster, more accurate identification of drug targets, optimizing high-throughput screening and enhancing drug repurposing efforts. The integration of machine learning models with large datasets has enabled a more predictive approach to drug development, leading to the discovery of novel antimicrobial agents and enhancing our understanding of microbial resistance mechanisms. CRISPR technology also holds promise in precisely editing microbial genomes to combat resistance, while the microbiome's role in infectious diseases underscores the importance of developing therapies that restore microbial balance to improve immune function and combat pathogens. Despite these advancements, several challenges remain, including issues related to data quality, model generalizability, and the integration of multi-technology approaches. Moreover, the clinical translation of these technologies requires overcoming substantial barriers, including regulatory hurdles, cost, and access to necessary infrastructure. Looking forward, the future of microbial drug discovery is likely to be characterized by the continued integration of AI, CRISPR, and microbiome-based therapies into a cohesive, personalized approach to infectious disease treatment. The vision for microbial drug discovery lies in the creation of a more dynamic and responsive drug development pipeline—one that can rapidly adapt to the emergence of new pathogens and the evolving landscape of AMR. In the near future, we may witness the widespread adoption of AI-driven systems that not only predict the emergence of resistance but also design novel antimicrobial agents that target pathogens with high precision. CRISPR-Cas systems could become integral tools in both drug discovery and therapeutic interventions, enabling direct genetic manipulation of microbial pathogens or human host cells to eradicate infections. The microbiome, too, will continue to play an increasingly prominent role in the development of personalized therapies that restore microbial equilibrium, thus enhancing immune function and preventing infection. A major goal for the future will be to ensure that these advanced technologies are accessible, affordable, and implemented equitably across global healthcare systems. This will require collaboration between researchers, healthcare professionals, and policymakers to develop frameworks that foster the translation of cutting-edge technologies into clinically effective treatments. Moreover, the continued refinement of regulatory standards, as well as the integration of AI and genetic tools into clinical practice, will be key to realizing the full potential of these innovations. Ultimately, the convergence of AI, CRISPR, and microbiome science holds the promise of a new era in microbial drug discovery, where the tools and therapies developed will not only address current challenges but also provide the flexibility and resilience needed to meet the infectious disease challenges of tomorrow.

Contribution of authors

- Ibrahim Abdulrazaq conceptualized the study and led the exploration of how Artificial Intelligence (AI) can be integrated into microbial drug discovery. He focused on AI-driven high-throughput screening, drug repurposing, and target identification strategies for overcoming antimicrobial resistance (AMR). He also contributed to drafting key sections on the role of AI in optimizing drug design and discovery pipelines.
- Shehu-Alimi Elelu contributed to the discussion on CRISPR technology and its application in microbial drug discovery. His work specifically centered on CRISPR-Cas systems for targeting resistance mechanisms in bacteria and exploring new antimicrobial targets. He provided critical insights into how CRISPR could revolutionize drug development by enhancing specificity and efficiency in combating resistant pathogens.
- Ganiyat Omotayo Ibrahim focused on the role of the human microbiome in drug discovery,

particularly how microbiome-based therapies can be integrated into drug design. Her research emphasized the potential of microbiome modulation in improving drug efficacy, minimizing side effects, and developing personalized treatment strategies for microbial infections.

- Idowu Afeez Temitope investigated the challenges of combining AI, CRISPR, and microbiome insights in microbial drug discovery. He provided valuable contributions on how these technologies could work synergistically to accelerate antimicrobial agent development, while also addressing issues related to data quality, availability, and the integration of multi-technology approaches in the drug discovery process.
- Abdulsalam Hawau Avoswahi explored research gaps in the field of drug discovery, focusing on underexplored pathways in microbiome-based therapies and the application of AI and CRISPR in overcoming antimicrobial resistance. She also contributed to identifying future research directions to enhance the effectiveness of antimicrobial treatments and strategies.
- Abdulkareem Tajuddeen Zakari contributed to the exploration of microbiome-based drug discovery and its potential in combating antimicrobial resistance. His research focused on identifying specific microbial populations that could be targeted for therapeutic interventions and exploring how these populations could aid in the development of novel antimicrobial agents.
- Mustapha Abdulsalam contributed to the conceptual framework of the study, analyzing how AI and CRISPR technologies could be leveraged for new antimicrobial therapies. He led discussions on the synergistic potential of combining these technologies to address the growing challenge of antimicrobial resistance (AMR) and provided recommendations for future research in the integration of these technologies with microbiome insights.

Acknowledgments

The authors would like to express their sincere gratitude to Professor (Mrs) R. N Ahmed, former Head of the Department of Microbiology, Faculty of Life Sciences, University of Ilorin, Nigeria, for her invaluable guidance, expert advice, and unwavering support throughout the research process. Her mentorship has been instrumental in shaping the direction of the study.

Conflict of Interest

The authors declare no conflicts of interest.

Funding

This research received no external funding.

Data Availability

Not available

References

1. Nanayakkara AK, Boucher HW, Fowler Jr VG, Jezek A, Outterson K, Greenberg DE. Antibiotic resistance in the patient with cancer: Escalating challenges and paths forward. CA Cancer J Clin. 2021;71(6):488-504.
2. Menz BD, Charani E, Gordon DL, Leather AJ, Moonesinghe SR, Phillips CJ. Surgical antibiotic prophylaxis in an era of antibiotic resistance: common resistant bacteria and wider considerations for practice. Infect Drug Resist. 2021;14:5235-52.
3. Yamanaka H, Tanaka E, Nakajima A, Furuya T, Ikari K, Taniguchi A, et al. A large observational cohort study of rheumatoid arthritis, IORRA: providing context for today's treatment options. Mod Rheumatol. 2020;30(1):1-6.
4. Brown DG, Wobst HJ. A decade of FDA-approved drugs (2010–2019): trends and future directions. J Med Chem. 2021;64(5):2312-38.
5. Willis LD, Chandler C. Quick fix for care, productivity, hygiene, and inequality: reframing the entrenched problem of antibiotic overuse. BMJ Glob Health. 2019;4(4):e001590.
6. Cardoso MH, Orozco RQ, Rezende SB, Rodrigues G, Oshiro KG, Cândido ES, et al. Computer-aided design of antimicrobial peptides: are we generating effective drug candidates? Front Microbiol. 2020;10:3097.
7. Tolios A, De Las Rivas J, Hovig E, Trouillas P, Scorilas A, Mohr T. Computational approaches in cancer multidrug resistance research: Identification of potential biomarkers, drug targets, and drug-target interactions. Drug Resist Updat. 2020;48:100662.
8. Kumar M, Sarma DK, Shubham S, Kumawat M, Verma V, Nina PB, et al. Futuristic non-antibiotic therapies to combat antibiotic resistance: A review. Front Microbiol. 2021;12:609459.
9. Boolchandani M, D'Souza AW, Dantas G.

Sequencing-based methods and resources to study antimicrobial resistance. Nat Rev Genet. 2019;20(6):356-70.
10. Abdulsalam M, Salihu AT, Usman HY, Usman MY. Protein Biosynthesis in Microorganisms: Mechanisms, Regulation, and Biotechnological Applications. World J Adv Res Rev. 2024;21(1):869-81.
11. Farha MA, Brown ED. Drug repurposing for antimicrobial discovery. Nat Microbiol. 2019;4(4):565-77.
12. Abdulsalam M, Musa IO, Livinus MU, Elelu SA, Ibrahim GO, Salami OL, et al. Blue Bioeconomy and Biomedical Innovation. In: Marine Bioprospecting for Sustainable Blue-bioeconomy. Cham: Springer Nature Switzerland; 2024. p. 143-57.
13. Ezzat A, Wu M, Li XL, Kwoh CK. Computational prediction of drug-target interactions using chemogenomic approaches: an empirical survey. Brief Bioinform. 2019;20(4):1337-57.
14. Saheed YK, Salau-Ibrahim TT, Abdulsalam M, Adeniji IA, Balogun BF. Modified bi-directional long short-term memory and hyperparameter tuning of supervised machine learning models for cardiovascular heart disease prediction in the mobile cloud environment. Biomed Signal Process Control. 2024;94:106319.
15. Abushaheen MA, Fatani AJ, Alosaimi M, Mansy W, George M, Acharya S, et al. Antimicrobial resistance, mechanisms, and its clinical significance. Dis Mon. 2020;66(6):100971.
16. Qin S, Xiao W, Zhou C, Pu Q, Deng X, Lan L, et al. Pseudomonas aeruginosa: pathogenesis, virulence factors, antibiotic resistance, interaction with the host, technology advances, and emerging therapeutics. Signal Transduct Target Ther. 2022;7(1):199.
17. Murugaiyan J, Kumar PA, Rao GS, Iskandar K, Hawser S, Hays JP, et al. Progress in alternative strategies to combat antimicrobial resistance: Focus on antibiotics. Antibiotics (Basel). 2022;11(2):200.
18. Balsalobre L, Blanco A, Alarcón T. Beta-lactams. In: Antibiotic drug resistance. Hoboken: John Wiley & Sons, Inc.; 2019. p. 57-72.
19. Bu F, Liu M, Xie Z, Chen X, Li G, Wang X. Targeted anti-biofilm therapy: Dissecting targets in the biofilm life cycle. Pharmaceuticals (Basel). 2022;15(10):1253.
20. Emmerich CH, Gamboa LM, Hofmann MC, Bonin-Andresen M, Arbach O, Schendel P, et al. Improving target assessment in biomedical research: the GOT-IT recommendations. Nat Rev Drug Discov. 2021;20(1):64-81.
21. Abdulsalam M, Fatima ZYU, Hasiya UA, Ummulkhuthum AT, Aisha WN, Muhammad FY. Deciphering the Genetic Code: Mechanisms, Evolution, and Implications for Biotechnology. World J Adv Res Rev. 2024;21(1):858-68.
22. Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health and disease. Cell Res. 2020;30(6):492-506.
23. Belsky JA, Tullius BP, Lamb MG, Sayegh R, Stanek JR, Auletta JJ. COVID-19 in immunocompromised patients: a systematic review of cancer, hematopoietic cell and solid organ transplant patients. J Infect. 2021;82(3):329-38.
24. Maruyama M, Rhee C, Utsunomiya T, Zhang N, Ueno M, Yao Z, et al. Modulation of the inflammatory response and bone healing. Front Endocrinol (Lausanne). 2020;11:386.
25. Zhang A, Meng K, Liu Y, Pan Y, Qu W, Chen D, et al. Absorption, distribution, metabolism, and excretion of nanocarriers in vivo and their influences. Adv Colloid Interface Sci. 2020;284:102261.
26. Hu X, Zhang H, Wang Y, Shiu BC, Lin JH, Zhang S, et al. Synergistic antibacterial strategy based on photodynamic therapy: Progress and perspectives. Chem Eng J. 2022;450:138129.
27. Shah T, Baloch Z, Shah Z, Cui X, Xia X. The intestinal microbiota: impacts of antibiotics therapy, colonization resistance, and diseases. Int J Mol Sci. 2021;22(12):6597.
28. Conti P, Ronconi G, Caraffa AL, Gallenga CE, Ross R, Frydas I, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVID-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020;34(2):327-31.
29. Bar Yehuda S, Axlerod R, Toker O, Zigman N, Goren I, Mourad V, et al. The association of inflammatory bowel diseases with autoimmune disorders: a report from the epi-IIRN. J Crohns Colitis. 2019;13(3):324-9.
30. Raheem A, Liang L, Zhang G, Cui S. Modulatory effects of probiotics during pathogenic infections with emphasis on immune regulation. Front Immunol. 2021;12:616713.
31. Stensland KD, DePorto K, Ryan J, Kaffenberger S, Reinstatler LS, Galsky M, et al. Estimating the rate and reasons of clinical trial failure in urologic oncology. Urol Oncol.

2021;39(3):154-60.
32. Basu S, Naha A, Veeraraghavan B, Ramaiah S, Anbarasu A. In silico structure evaluation of BAG3 and elucidating its association with bacterial infections through protein-protein and host-pathogen interaction analysis. J Cell Biochem. 2022;123(1):115-27.
33. Saheed YK, Balogun BF, Odunayo BJ, Abdulsalam M. Microarray gene expression data classification via Wilcoxon sign rank sum and novel Grey Wolf optimized ensemble learning models. IEEE/ACM Trans Comput Biol Bioinform. 2023;20(6):3575-87.
34. Đorđević S, Gonzalez MM, Conejos-Sánchez I, Carreira B, Pozzi S, Acúrcio RC, et al. Current hurdles to the translation of nanomedicines from the bench to the clinic. Drug Deliv Transl Res. 2022;12(3):500-25.
35. Gulliver EL, Young RB, Chonwerawong M, D'Adamo GL, Thomason T, Widdop JT, et al. The future of microbiome-based therapeutics. Aliment Pharmacol Ther. 2022;56(2):192-208.
36. Abdulsalam M, Natour S, Rabiu IB, Abdulazeez M. Microbial Magic: Decoding the Impact of Hypoxia on Exercise Physiology through Microbiota Dynamics. Biol Sci. 2024;4(3):736-45.
37. Dias R, Torkamani A. Artificial intelligence in clinical and genomic diagnostics. Genome Med. 2019;11(1):70.
38. Thapa C, Camtepe S. Precision health data: Requirements, challenges and existing techniques for data security and privacy. Comput Biol Med. 2021;129:104130.
39. Abdulsalam M. Exploring the Therapeutic Promise of Cationic Antibacterial Peptides. Biol Sci. 2024;4(3):692-700.
40. Musa IO, Isibor PO, Samuel JO, Mustapha A, Akande S, Adeniji H. Introduction to Nanotoxicology. In: Environmental Nanotoxicology: Combatting the Minute Contaminants. Cham: Springer Nature Switzerland; 2024. p. 1-22.
41. Lin H, He QY, Shi L, Sleeman M, Baker MS, Nice EC. Proteomics and the microbiome: pitfalls and potential. Expert Rev Proteomics. 2019;16(6):501-11.
42. Abdulsalam M, Amina AA, Ummulkhair AY, Zainab HF. Advances in understanding the interplay between Mutagenesis and DNA repair: Implications for Genomic Stability and Evolution. Int J Sci Acad Res. 2023;4(10):6428-38.
43. Abdulsalam M, Hamisu AA, Ahmad AM, Wakili FB, Annu FS, Garba MM. Microbiome Dynamics and Strategic Management Strategies: Exploring Synergies between Integrative Medicine Modalities and Microbial Balance. Biol Sci. 2024;4(3):725-35.
44. Su M, Zhang Z, Zhou L, Han C, Huang C, Nice EC. Proteomics, personalized medicine, and cancer. Cancers (Basel). 2021;13(11):2512.
45. Guo XY, Liu XJ, Hao JY. Gut microbiota in ulcerative colitis: insights on pathogenesis and treatment. J Dig Dis. 2020;21(3):147-59.
46. Wu Y, Battalapalli D, Hakeem MJ, Selamneni V, Zhang P, Draz MS, et al. Engineered CRISPR-Cas systems for the detection and control of antibiotic-resistant infections. J Nanobiotechnology. 2021;19(1):401.
47. Shan S. The controls of nutrient limitation on resource allocation belowground (dissertation). Oxford (OH): Miami University; 2019.
48. Yella A, Kondam A. Big Data Integration and Interoperability: Overcoming Barriers to Comprehensive Insights. Adv Comput Sci. 2022;5(1).
49. Uddin F, Rudin CM, Sen T. CRISPR gene therapy: applications, limitations, and implications for the future. Front Oncol. 2020;10:1387.
50. Lopatkin AJ, Collins JJ. Predictive biology: modeling, understanding and harnessing microbial complexity. Nat Rev Microbiol. 2020;18(9):507-20.
51. Abdulsalam M, Hamisu AA, Ahmad AM, Wakili FB, Rabiu IB, Burodo RA, et al. Synergies at the Intersection: Exploring the Role of Bioinformatics in Enhancing Physiotherapy and Nursing Practice. Biol Sci. 2024;4(3):712-24.
52. Failli M, Paananen J, Fortino V. Prioritizing target-disease associations with novel safety and efficacy scoring methods. Sci Rep. 2019;9(1):9852.
53. Kalelkar PP, Riddick M, García AJ. Biomaterial-based antimicrobial therapies for the treatment of bacterial infections. Nat Rev Mater. 2022;7(1):39-54.
54. Haider T, Pandey V, Banjare N, Gupta PN, Soni V. Drug resistance in cancer: mechanisms and tackling strategies. Pharmacol Rep. 2020;72(5):1125-51.
55. Melo MC, Maasch JR, de la Fuente-Nunez C. Accelerating antibiotic discovery through artificial intelligence. Commun Biol. 2021;4(1):1050.
56. Van Esse HP, Reuber TL, van der Does D. Genetic modification to improve disease resistance in crops. New Phytol. 2020;225(1):70-86.
57. Abdulsalam M, Tiamiyu BB, Abdulrazaq I, Salam OL. Comparative Antimicrobial

Properties of a Consortium of Nauclea latifolia Sm. and Ocimum gratissium L. Extracts with Their CuO Nanoparticle Multiplexes. Biol Sci. 2023;3(1):386-93.
58. Branda F, Scarpa F. Implications of Artificial Intelligence in Addressing Antimicrobial Resistance: Innovations, Global Challenges, and Healthcare's Future. Antibiotics (Basel). 2024;13(6):502.
59. Mistry J, Ganesh A. An Analysis of IoT-Based Solutions for Congenital Heart Disease Monitoring and Prevention. J Xidian Univ. 2023;17(7):325-34.
60. van Belkum A, Bachmann TT, Lüdke G, Lisby JG, Kahlmeter G, Mohess A, et al. Developmental roadmap for antimicrobial susceptibility testing systems. Nat Rev Microbiol. 2019;17(1):51-62.